# GSK invests $100M to boost shingles vaccine adjuvant production in Hamilton, Montana

GlaxoSmithKline is spending $100 million to increase production at its vaccine facility in Hamilton, Montana, which makes adjuvants for vaccines including Shingrix. The expansion aims to address demand since Shingrix was approved in the US in 2017.

- Type: Expansion
- Announced: 2019-04-29
- Where: Hamilton, Montana, United States
- Value: $100.0M
- Status: announced
- Products: vaccine adjuvants, Shingrix

## Companies

- [GlaxoSmithKline](https://endata.com/companies/5584.md)

## Sources

- [doi.org](https://doi.org/10.1021/cen-09717-buscon15), 2019-04-29: "GlaxoSmithKline is spending $100 million to increase production at its vaccine facility in Hamilton, Montana."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.